ALUMIS INC (ALMS) Stock News
NASDAQ:ALMS - Nasdaq - US0223071020 - Common Stock - Currency: USD
ALMS Latest News, Press Relases and Analysis
Alumis to Present at the Jefferies Global Healthcare Investor Conference
Alumis to present at Jefferies Global Healthcare Conference on June 4, 2025...
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis...
Alumis Completes Merger with ACELYRIN
Alumis Completes Merger with ACELYRIN...
Alumis Stockholders Approve Merger with ACELYRIN
Alumis Stockholders Approve Merger with ACELYRIN...
What's Going On With Alumis Shares Tuesday?
Alumis stock is trading higher on Tuesday after the company announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals.
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today
Mentions: SLRN
Why Investors Were Avoiding GeneDx Holdings Stock This Week
The company crushed analyst estimates in its first quarter, but for many investors it didn't crush them enough. Regardless, several analysts cut their price targets just after the earnings release was published. With a nearly 39% stock price decline this week, according to data compiled by S&P Global Market Intelligence, GeneDx Holdings (NASDAQ: WGS) was deep in the doghouse with investors.
Acelyrin urges stockholders to vote for proposed merger with Alumis
ACELYRIN (SLRN) reiterated its confidence that the proposed combination with Alumis (ALMS) is the best path forward and the most value-maximizing outcome for all ACELYRIN stockholders. Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the independent transaction committee, said, “The ACELYRIN Board and management team are confident that the proposed merger with Alumis represents the most value-maximizing path forward for our company’s stockholders. The agreement with Alumis fo
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Mentions: SLRN
Acelyrin should liquidate instead of merging with Alumis, investor says
Trium Capital is the latest firm to push a biotech “zombie” to shut down, claiming in a regulatory filing there is more upside to a liquidation than Acelyrin’s planned merger.
3 Biopharmaceutical Stocks Bucking the Sell-Off
Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Alumis and ACELYRIN file joint definitive proxy statement for proposed merger, expected to close in 2Q 2025...